KR101546111B1 - 신규한 ｓＥＨ 억제제 및 그의 용도 - Google Patents
신규한 ｓＥＨ 억제제 및 그의 용도 Download PDFInfo
- Publication number
- KR101546111B1 KR101546111B1 KR1020107010233A KR20107010233A KR101546111B1 KR 101546111 B1 KR101546111 B1 KR 101546111B1 KR 1020107010233 A KR1020107010233 A KR 1020107010233A KR 20107010233 A KR20107010233 A KR 20107010233A KR 101546111 B1 KR101546111 B1 KR 101546111B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- amino
- phenyl
- trifluoromethyl
- cyclohexanecarboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(C)(CC*)CC(C)C(*)=N Chemical compound C*C(C)(CC*)CC(C)C(*)=N 0.000 description 8
- KSCGUMADNLNELG-UHFFFAOYSA-N CN(C)c(cc1Cl)ccc1C#N Chemical compound CN(C)c(cc1Cl)ccc1C#N KSCGUMADNLNELG-UHFFFAOYSA-N 0.000 description 1
- DMMKUHDEXFEEKM-UHFFFAOYSA-O Cc1cc(/C(/N)=N/N=[NH2+])ccc1CN Chemical compound Cc1cc(/C(/N)=N/N=[NH2+])ccc1CN DMMKUHDEXFEEKM-UHFFFAOYSA-O 0.000 description 1
- ZKZAXYFDOARCSI-HOTGVXAUSA-N Cc1nc(NC)nc(CC[C@H](CCC2)C[C@H]2C(NCc(cccc2)c2OC(F)(F)F)=O)n1 Chemical compound Cc1nc(NC)nc(CC[C@H](CCC2)C[C@H]2C(NCc(cccc2)c2OC(F)(F)F)=O)n1 ZKZAXYFDOARCSI-HOTGVXAUSA-N 0.000 description 1
- HMQKWQYOMAACKL-TUCDSHDJSA-N Cc1nc(NC)nc(N[C@@H](CCC2)C[C@@H]2C(NC[C@H]2C=CC(OC)=CC2C(F)(F)F)=O)n1 Chemical compound Cc1nc(NC)nc(N[C@@H](CCC2)C[C@@H]2C(NC[C@H]2C=CC(OC)=CC2C(F)(F)F)=O)n1 HMQKWQYOMAACKL-TUCDSHDJSA-N 0.000 description 1
- GNFQYEFIPLLBLG-BJHJDKERSA-N N[C@H](CC1)CC[C@H]1C(NCc(ccc(C#N)c1)c1Cl)=O Chemical compound N[C@H](CC1)CC[C@H]1C(NCc(ccc(C#N)c1)c1Cl)=O GNFQYEFIPLLBLG-BJHJDKERSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/46—Phenazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97915407P | 2007-10-11 | 2007-10-11 | |
| US60/979,154 | 2007-10-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100075619A KR20100075619A (ko) | 2010-07-02 |
| KR101546111B1 true KR101546111B1 (ko) | 2015-08-20 |
Family
ID=40549589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020107010233A Active KR101546111B1 (ko) | 2007-10-11 | 2008-10-10 | 신규한 ｓＥＨ 억제제 및 그의 용도 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8173805B2 (https=) |
| EP (1) | EP2214487B1 (https=) |
| JP (1) | JP5372943B2 (https=) |
| KR (1) | KR101546111B1 (https=) |
| CN (1) | CN101896065B (https=) |
| AU (1) | AU2008310732B2 (https=) |
| BR (1) | BRPI0817542A2 (https=) |
| CA (1) | CA2702265C (https=) |
| CO (1) | CO6270285A2 (https=) |
| CR (1) | CR11423A (https=) |
| CY (1) | CY1114865T1 (https=) |
| DK (1) | DK2214487T3 (https=) |
| DO (1) | DOP2010000101A (https=) |
| EA (1) | EA018414B1 (https=) |
| ES (1) | ES2445444T3 (https=) |
| HR (1) | HRP20140105T1 (https=) |
| IL (1) | IL204889A (https=) |
| MA (1) | MA31761B1 (https=) |
| MX (1) | MX2010003942A (https=) |
| MY (1) | MY157116A (https=) |
| NZ (1) | NZ584471A (https=) |
| PL (1) | PL2214487T3 (https=) |
| PT (1) | PT2214487E (https=) |
| RS (1) | RS53180B (https=) |
| SI (1) | SI2214487T1 (https=) |
| UA (1) | UA107444C2 (https=) |
| WO (1) | WO2009049157A1 (https=) |
| ZA (1) | ZA201002465B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2097378B1 (en) | 2006-11-03 | 2012-09-12 | GlaxoSmithKline LLC | Novel seh inhibitors and their use |
| ES2404580T3 (es) | 2007-10-11 | 2013-05-28 | Glaxosmithkline Llc | Novedosos inhibidores de la ehs y uso de los mismos |
| WO2009049157A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| FR2948027A1 (fr) | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US8809552B2 (en) * | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| WO2015104422A1 (en) | 2014-01-13 | 2015-07-16 | Basf Se | Dihydrothiophene compounds for controlling invertebrate pests |
| WO2015155129A1 (en) * | 2014-04-07 | 2015-10-15 | Basf Se | Diaminotriazine compound |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2020074549A1 (en) * | 2018-10-10 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
| WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
| EP4618985A1 (en) | 2022-11-18 | 2025-09-24 | Universitat De Barcelona | Dual inhibitors of sigma-1 receptor and soluble epoxide hydrolase and their use in the treatment of pain |
| WO2026058000A2 (en) | 2024-09-13 | 2026-03-19 | Ucl Business Ltd | Methods |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| WO2007106525A1 (en) | 2006-03-13 | 2007-09-20 | The Regents Of The University Of California | Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5420283A (en) | 1993-08-02 | 1995-05-30 | Pfizer Inc. | Resolution of (R)-2-benzylsuccinic acid 4-[4-(N-t-butoxycarbonylmethylamino)-piperidine] amide |
| CA2348740A1 (en) | 1998-12-23 | 2000-07-06 | Ruth R. Wexler | Thrombin or factor xa inhibitors |
| ES2385931T3 (es) | 2000-07-07 | 2012-08-03 | Spectrum Pharmaceuticals, Inc. | MÉTODOS PARA EL TRATAMIENTO DE NEUROPATíA PERIFÉRICA INDUCIDA POR UNA ENFERMEDAD Y AFECCIONES RELACIONADAS. |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| AU9598601A (en) | 2000-10-20 | 2002-04-29 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| WO2002058736A2 (en) | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| US6989385B2 (en) | 2000-12-21 | 2006-01-24 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| DE60222264T2 (de) | 2001-06-29 | 2008-01-03 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Phenylpyrazolderivate als seh-inhibitoren |
| US20030055249A1 (en) | 2001-07-17 | 2003-03-20 | Fick David B. | Synthesis and methods of use of pyrimidine analogues and derivatives |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| KR100875362B1 (ko) | 2002-02-05 | 2008-12-22 | 아스텔라스세이야쿠 가부시키가이샤 | 2,4,6-트리아미노-1,3,5-트리아진 유도체 |
| BR0310061A (pt) | 2002-05-16 | 2005-03-01 | Pharmacia Corp | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições |
| US20050197350A1 (en) | 2003-03-31 | 2005-09-08 | Taisho Pharmaceutical Co., Ltd. | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| TW200519094A (en) | 2003-07-02 | 2005-06-16 | Vertex Pharma | Pyrimidines useful as modulators of voltage-gated ion channels |
| ATE547404T1 (de) | 2003-09-22 | 2012-03-15 | Msd Kk | Piperidinderivate |
| GB0401269D0 (en) | 2004-01-21 | 2004-02-25 | Astrazeneca Ab | Compounds |
| EP1794135A1 (en) | 2004-09-27 | 2007-06-13 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| TW200628463A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | Heteroaryl compounds |
| JP2008523103A (ja) | 2004-12-14 | 2008-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｅｒｋプロテインキナーゼのピリミジンインヒビターおよびその使用 |
| US20060276515A1 (en) | 2005-05-06 | 2006-12-07 | Cywin Charles L | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same |
| JP2009511489A (ja) * | 2005-10-07 | 2009-03-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシド加水分解酵素阻害剤として有益なｎ−置換ピリジノン又はピリミジノン化合物 |
| CA2637620A1 (en) * | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| EP2097378B1 (en) * | 2006-11-03 | 2012-09-12 | GlaxoSmithKline LLC | Novel seh inhibitors and their use |
| US20100210655A1 (en) | 2007-10-11 | 2010-08-19 | Yun Ding | NOVEL sEH INHIBITORS AND THEIR USE |
| ES2404580T3 (es) | 2007-10-11 | 2013-05-28 | Glaxosmithkline Llc | Novedosos inhibidores de la ehs y uso de los mismos |
| WO2009049157A1 (en) | 2007-10-11 | 2009-04-16 | Smithkline Beecham Corporation | Novel seh inhibitors and their use |
| US8450843B2 (en) | 2007-10-12 | 2013-05-28 | Nec Corporation | Semiconductor device and method for designing the same |
| WO2009070497A1 (en) | 2007-11-28 | 2009-06-04 | Smithkline Beecham Corporation | SEH AND 11 β-HSD1 INHIBITORS AND THEIR USE |
| EP2224928A4 (en) | 2007-12-06 | 2012-02-15 | Glaxosmithkline Llc | NOVEL INHIBITORS OF SEH AND THEIR USE |
| US20100311776A1 (en) | 2008-01-30 | 2010-12-09 | Smithkline Beecham Corporation | Novel sEH Inhibitors and their Use |
| JP2011510996A (ja) | 2008-01-30 | 2011-04-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 新規ｓＥＨ阻害剤およびその使用 |
| WO2009097475A1 (en) | 2008-01-30 | 2009-08-06 | Smithkline Beecham Corporation | NOVEL sEH INHIBITORS AND THEIR USE |
| WO2010011917A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Llc | SEH AND 11β-HSD1 DUAL INHIBITORS |
-
2008
- 2008-10-10 WO PCT/US2008/079517 patent/WO2009049157A1/en not_active Ceased
- 2008-10-10 EA EA201070442A patent/EA018414B1/ru not_active IP Right Cessation
- 2008-10-10 UA UAA201005720A patent/UA107444C2/uk unknown
- 2008-10-10 RS RS20140078A patent/RS53180B/sr unknown
- 2008-10-10 MY MYPI2010001613A patent/MY157116A/en unknown
- 2008-10-10 AU AU2008310732A patent/AU2008310732B2/en not_active Ceased
- 2008-10-10 PT PT88383146T patent/PT2214487E/pt unknown
- 2008-10-10 HR HRP20140105AT patent/HRP20140105T1/hr unknown
- 2008-10-10 US US12/682,073 patent/US8173805B2/en active Active
- 2008-10-10 DK DK08838314.6T patent/DK2214487T3/da active
- 2008-10-10 CA CA2702265A patent/CA2702265C/en active Active
- 2008-10-10 ES ES08838314.6T patent/ES2445444T3/es active Active
- 2008-10-10 NZ NZ584471A patent/NZ584471A/en unknown
- 2008-10-10 BR BRPI0817542-0A2A patent/BRPI0817542A2/pt active Search and Examination
- 2008-10-10 KR KR1020107010233A patent/KR101546111B1/ko active Active
- 2008-10-10 CN CN200880120430XA patent/CN101896065B/zh active Active
- 2008-10-10 JP JP2010529081A patent/JP5372943B2/ja active Active
- 2008-10-10 SI SI200831142T patent/SI2214487T1/sl unknown
- 2008-10-10 PL PL08838314T patent/PL2214487T3/pl unknown
- 2008-10-10 MX MX2010003942A patent/MX2010003942A/es active IP Right Grant
- 2008-10-10 EP EP08838314.6A patent/EP2214487B1/en active Active
-
2010
- 2010-04-06 IL IL204889A patent/IL204889A/en active IP Right Grant
- 2010-04-08 ZA ZA2010/02465A patent/ZA201002465B/en unknown
- 2010-04-08 MA MA32751A patent/MA31761B1/fr unknown
- 2010-04-09 US US12/757,089 patent/US8212032B2/en active Active
- 2010-04-09 DO DO2010000101A patent/DOP2010000101A/es unknown
- 2010-05-06 CO CO10054262A patent/CO6270285A2/es active IP Right Grant
- 2010-05-11 CR CR11423A patent/CR11423A/es unknown
-
2014
- 2014-02-18 CY CY20141100122T patent/CY1114865T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| WO2007106525A1 (en) | 2006-03-13 | 2007-09-20 | The Regents Of The University Of California | Piperidinyl, indolyl, pirinidyl, morpholinyl and benzimidazolyl urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of hypertension, inflammations and other diseases |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101546111B1 (ko) | 신규한 ｓＥＨ 억제제 및 그의 용도 | |
| US20100261743A1 (en) | Novel seh inhibitors and their use | |
| US20100210655A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| EP2209376B1 (en) | Novel seh inhibitors and their use | |
| US20100324076A1 (en) | Novel sEH Inhibitors and their Use | |
| EP2240026A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| EP2240025A1 (en) | NOVEL sEH INHIBITORS AND THEIR USE | |
| HK1141211B (en) | Novel seh inhibitors and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20100510 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20131008 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150216 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20150803 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20150813 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20150813 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| FPAY | Annual fee payment |
Payment date: 20180628 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180628 Start annual number: 4 End annual number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20190624 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190624 Start annual number: 5 End annual number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20200624 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200624 Start annual number: 6 End annual number: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20210723 Year of fee payment: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210723 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20220722 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20220722 Start annual number: 8 End annual number: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230802 Start annual number: 9 End annual number: 9 |